178 related articles for article (PubMed ID: 28484589)
1.
Cleven AHG; Suijker J; Agrogiannis G; Briaire-de Bruijn IH; Frizzell N; Hoekstra AS; Wijers-Koster PM; Cleton-Jansen AM; Bovée JVMG
Clin Sarcoma Res; 2017; 7():8. PubMed ID: 28484589
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
6. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Schaefer IM; Hornick JL; Bovée JVMG
Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
8. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476
[TBL] [Abstract][Full Text] [Related]
9. Beyond the Influence of
Venneker S; Kruisselbrink AB; Baranski Z; Palubeckaite I; Briaire-de Bruijn IH; Oosting J; French PJ; Danen EHJ; Bovée JVMG
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266275
[TBL] [Abstract][Full Text] [Related]
10. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
11. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH is sufficient to initiate enchondromatosis in mice.
Hirata M; Sasaki M; Cairns RA; Inoue S; Puviindran V; Li WY; Snow BE; Jones LD; Wei Q; Sato S; Tang YJ; Nadesan P; Rockel J; Whetstone H; Poon R; Weng A; Gross S; Straley K; Gliser C; Xu Y; Wunder J; Mak TW; Alman BA
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2829-34. PubMed ID: 25730874
[TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
Mondesir J; Willekens C; Touat M; de Botton S
J Blood Med; 2016; 7():171-80. PubMed ID: 27621679
[TBL] [Abstract][Full Text] [Related]
14. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.
Pathak P; Jha P; Purkait S; Sharma V; Suri V; Sharma MC; Faruq M; Suri A; Sarkar C
J Neurooncol; 2015 Feb; 121(3):489-97. PubMed ID: 25479829
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
[TBL] [Abstract][Full Text] [Related]
16. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
17. Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Kim HJ; Fei X; Cho SC; Choi BY; Ahn HC; Lee K; Seo SY; Keum YS
Bioorg Med Chem Lett; 2015 Dec; 25(23):5625-31. PubMed ID: 26508549
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
[TBL] [Abstract][Full Text] [Related]
19. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
[TBL] [Abstract][Full Text] [Related]
20. Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs.
Roessner A; Franke S; Schreier J; Ullmann S; Karras F; Jechorek D
Pathol Res Pract; 2022 Nov; 239():154172. PubMed ID: 36274381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]